Why Is VIKING THERAPEUTICS (VKTX) Stock Up Today?

Why VKTX stock is up today

Viking Therapeutics shares surged 35.67% to $40.85 on Tuesday driven by positive trial data for its obesity drug candidate, VK2735. The stock’s sharp rise reflects investor optimism that the drug could retain a significant portion of weight loss with less frequent dosing, potentially offering a competitive alternative to existing GLP-1 drugs.

What Happened

Viking Therapeutics announced top-line data from a maintenance study of its dual GLP-1/GIP drug candidate, VK2735, in obesity and type 2 diabetes. The study showed that patients retained up to 97% of prior weight loss with every-other-week dosing and approximately 90% with monthly dosing. This suggests the drug could offer a more convenient treatment option for patients, which may help improve adherence and long-term weight management. Analysts and industry experts have highlighted the potential for VK2735 to compete with market leaders like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. The stock’s strong performance follows recent coverage from multiple outlets emphasizing the drug’s potential to simplify treatment regimens while maintaining efficacy.

What The Data Shows

The stock’s price trend over the past eight sessions shows a 20.7% gain, from $31.98 to $38.58, before today’s surge. Unusual options activity in the last 36 hours includes three notable prints, with $9.6 million in call premiums and no put premiums. The largest single print was $3.4 million. On the 52-week tape, the stock printed 22 fresh 52-week highs and two fresh 52-week lows on the same day. Insider transactions in the last 90 days include three sales totaling $6.3 million, with the most recent occurring on July 29, 2026.

What To Watch

Viking Therapeutics is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any further developments in the drug’s clinical pipeline, as well as potential regulatory milestones.